Q4 2024 13F Holders as of 31 Dec 2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
99.6M
-
Number of holders
-
596
-
Total 13F shares, excl. options
-
94.4M
-
Shares change
-
+1.41M
-
Total reported value, excl. options
-
$12.9B
-
Value change
-
+$230M
-
Put/Call ratio
-
0.94
-
Number of buys
-
292
-
Number of sells
-
-281
-
Price
-
$136.50
Significant Holders of NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) as of Q4 2024
694 filings reported holding NBIX - NEUROCRINE BIOSCIENCES INC - Common Stock as of Q4 2024.
NEUROCRINE BIOSCIENCES INC - Common Stock (NBIX) has 596 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 94.4M shares
of 99.6M outstanding shares and own 94.75% of the company stock.
Largest 10 shareholders include BlackRock, Inc. (14.8M shares), VANGUARD GROUP INC (10.1M shares), STATE STREET CORP (4.89M shares), Dodge & Cox (3.02M shares), CITADEL ADVISORS LLC (2.54M shares), RENAISSANCE TECHNOLOGIES LLC (2.49M shares), AQR CAPITAL MANAGEMENT LLC (1.9M shares), GEODE CAPITAL MANAGEMENT, LLC (1.88M shares), Bellevue Group AG (1.82M shares), and MORGAN STANLEY (1.57M shares).
This table shows the top 596 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.